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rare, multisystemic disease, caused by an inherited defect in
the Fas apoptotic pathway, characterized by a chronic non-
malignant lymphoid accumulation and autoimmune manifesta-
tions. Lung, kidney, liver, and gut inﬁltration is described in
severe, multisystemic cases; so far there has been no description
of hepatopulmonary syndrome (HPS), for which orthotopic liver
transplantation (OLT) is currently the only known effective
treatment.
A teenage boy, diagnosed with ALPS at 4 years of age (lymph
nodes enlargement, splenomegaly, immune cytopenias), was sta-
ble until 13 years of age, when he developed insidious hypoxemia
(PaO2 = 46.7 mmHg).
He was diagnosed with HPS on the basis of hypoxemia, non-
cirrhotic liver disease with portal hypertension, and pulmonary
vascular dilatation (intrapulmonary shunt = 45%). He was treated
with oxygen (maximum 6 L/min), prednisolone and sirolimus.
There was signiﬁcant regression of all manifestations of ALPS,
except for the pulmonary symptoms, therefore, after evaluation
in referral centers in England, OLT was proposed. Since he was
to undergo major surgery, sirolimus, which has wound-healing
problems, was switched to mycophenolate mofetil (MMF).Journal of Hepatology 20
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factor-a; VEGF, vascular endothelial growth factor.pulmonary symptoms and reduction of oxygen needs. The intra-
pulmonary shunt decreased from 45% to 0% in less than a year,
and it has not changed since (18 months after complete normal-
ization), on continued treatment with MMF. Indication for OLT
was suspended. In the last year, lymphoid proliferation increased
again, with huge splenomegaly, but no recurrence of HPS. The
addition of sirolimus to MMF produced again a rapid resolution
of lymphoid proliferation.
The dramatic and unexpected regression of HPS may have
been due to inhibition of angiogenesis and nitric oxide (NO) pro-
duction by MMF (both important pathways/mediators in HPS
pathogenesis). Therefore, we propose to perform clinical trials
with MMF, and/or other angiogenesis and NO inhibitors, on a
long-term treatment basis, to conﬁrm their potential as a valid
alternative to medical treatment of HPS.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
ALPS is a rare genetic disorder of disrupted lymphocyte homeo-
stasis caused by defective Fas-mediated apoptosis [1,2]. Manifes-
tations usually appear in the ﬁrst 5 years of life. Patients can
develop a myriad of clinical manifestations, including non-
malignant lymphoproliferative manifestations, life-long autoim-
mune disease, and increased propensity to malignancy. Although
lung lymphoid inﬁltration has been described, HPS has never
been reported in association with ALPS [1,2].
HPS is a serious vascular complication that occurs in patients
with liver disease and/or portal hypertension, and causes an
abnormal age-corrected alveolar–arterial oxygen gradient [5,6].
The diagnosis of HPS in a child with liver disease is established
by demonstration of hypoxemia (PaO2 <80 mmHg) or elevated
alveolar–arterial oxygen gradient on arterial blood gas analysis
(>15 mmHg), and the presence of intrapulmonary shunting using
contrast-enhanced echocardiography or technetium-99 m-
labeled macroaggregated albumin (99mTc-MAA) perfusion
scan. The diffusing capacity may be reduced because the13 vol. 58 j 630–633
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alveolar–capillary interface is too wide to allow for complete
equilibration of carbon monoxide with hemoglobin [3].
ALPS therapy is primarily directed toward autoimmune man-
ifestations, particularly autoimmune cytopenias. Patients usually
respond to courses of immunosuppression, steroids being the
ﬁrst line treatment. MMF, sirolimus and tacrolimus are effective
in chronic recalcitrant autoimmune cytopenias and major lym-
phoid proliferation, and may spare the use of steroids [2,4].
Currently, OLT is the only established effective therapy for
HPS, with priority criteria over other patients enrolled in the list,
since these patients have higher morbidity and mortality [5,6].
We report the clinical course of a teenage boy with ALPS and
chronic liver disease with portal hypertension that evolved to
HPS. He was treated with steroids and sirolimus with improve-
ment in all but pulmonary symptoms, and subsequently, with
MMF treatment, there was a complete resolution of the HPS.Fig. 1. Clinical features of the patient at 13 years of age (A–C) and 9 months
after starting MMF treatment (D and E). (A) Signs of central cyanosis, (B)
abdominal distension (giant splenomegaly) and slight collateral venous circula-
tion, (C) digital clubbing, (D) general improved condition and catch-up growth, no
signs of central cyanosis and no abdominal distension, and (E) no digital clubbing.
(This ﬁgure appears in color on the web.)
A
B
C
Fig. 2. Liver histology. (A) Discrete lymphocytic inﬁltrate without necroinﬂam-
matory activity interface and no ﬁbrous expansion nor formation of ﬁbrous septa;
(B and C) severe sinusoidal ﬁbrosis and mild/moderate ﬁbrosis pericentrovenular,
with areas of congestion/sinusoidal blood dilatation and numerous lymphocytes.
(This ﬁgure appears in color on the web.)Case report
A thirteen-year-old boy, ﬁrst and unique child of a healthy Portu-
guese non-consanguineous couple, was diagnosed at the age of
4 years with ALPS on the basis of two major criteria (chronic
lymph nodes enlargement and progressive splenomegaly, and
lymphocytosis with 33% of double-negative (i.e., CD4/CD8) T
cells), and two minor criteria (autoimmune cytopenias (thrombo-
cytopenia, haemolytic anemia, neutropenia) and hypergamma-
globulinemia). The diagnosis was later conﬁrmed by genetic
analysis that identiﬁed a mutation in the Fas ligand (CD95L) gene
(single bp deletion in exon 2) [2].
At 9 years of age, he had severe nose and gingival bleeding. He
was pale and had generalized lymphadenopathy and hepato-
splenomegaly. Laboratory evaluation showed anemia (Coombs
test positive) and thrombocytopenia. He received red blood cell
transfusions, intravenous immunoglobulin, and prednisolone.
Subsequently, his condition remained stable, and he was treated
with prednisolone 5 mg every other day.
At the age of 13 years, he had dyspnea on exertion with pro-
gression to shortness of breath and tachypnea at rest. He was thin
and small for his age (weight – 29.3 kg, p <5; height – 140.5 cm, p
<5). He had signs of central cyanosis (lips, ears), mildly jaundiced
sclera, facial spider nevi, palmar erythema and marked digital
clubbing (Fig. 1A–C). Peripheral oxygen saturation was 87% (he
needed oxygen, 4 L/min via nasal cannula, to maintain oxygen
saturation around 93–95%). He had cervical lymphadenopathy
(1 cm). Pulmonary and cardiac auscultation was unremarkable.
He had a slight abdominal collateral venous circulation. The liver
edge was palpable 4 cm below the right margin rib, and the
spleen 12 cm below the margin rib. Laboratory evaluation was
as follows: Hb 10.6 g/dL (Coombs test positive), WBC
7.16  109/L (lymphocyte 46%), platelets 8.5  109/L, tBil
1.88 mg/dL, cBil 0.97 mg/dL, AST 160 UI/L (N <34), ALT 110 UI/L
(N <44), GGT 80 UI/L (N <66), albumin 35.2 g/dL, APPT 31.200(N:
29.400), IgG-2920 mg/dL, IgA-1480 mg/dL, ANA‘s 1/360, anti-
smooth muscle 1/40, double negative (CD4/CD8) T cell in
peripheral blood 18.1%.
The abdominal ultrasound with Doppler study showed a nod-
ular coarse liver with no focal lesions. The hepatic vessels had
normal ﬂow velocities and waveforms. There was a giant spleno-
megaly (20 cm) with small varices and no ascites. The liver his-
tology showed severe sinusoisal ﬁbrosis (with sinusoidal bloodJournal of Hepatology 201dilatation, numerous lymphocytes, and distortion of trabeculae),
mild/moderate pericentrovenular ﬁbrosis, and features of nodu-
lar regenerative hyperplasia (Fig. 2A–C). The upper endoscopy
showed one grade II varix in the lower esophagus, mild hyperten-
sive gastropathy, and non-speciﬁc duodenitis signs.3 vol. 58 j 630–633 631
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The pulmonary assessment established the presence of hyp-
oxemia (pH 7.472, PaO2 46.7 mmHg, PaCO2 31.9 mmHg, Hgb
17.7 g/dl, Sat O2 77.3%, oxi Hgb 76.8%, carboxi Hgb 0,3%, met
Hgb 0.3%, deoxi Hgb 22,6%).
The lung function test revealed no signiﬁcant ﬂow limitation,
but the diffusing capacity was reduced (35%). The high resolution
CT scan excluded the presence of inﬁltrative disease. The con-
trast-enhanced echocardiography and a 99mTc-MAA perfusion
scan both conﬁrmed the presence of intrapulmonary vascular
shunt (right to left shunt of 43.2%).
The patient‘s condition was discussed with national and inter-
national experts. It was decided to increase the prednisolone dose
to 30 mg daily for a month, with progressive slow reduction to
10 mg, plus sirolimus 1 mg daily. For the following 6 months,
there was a signiﬁcant regression of ALPS manifestations:
decrease in lymphadenopathy and particularly in spleen size, res-
olution of cytopenias, slight improvement in liver enzymes, sig-
niﬁcant reduction in peripheral double negative (CD4/CD8) T
cells, and catch-up growth, despite the steroid therapy in daily
doses. However, pulmonary symptoms did not improve
signiﬁcantly.
At that point in time, OLT was considered. Three months
later, he was evaluated in England (ﬁrst in Newcastle, later in
Birmingham). Meanwhile, the patient’s condition worsened
(growing needs of oxygen up to 6 L/min and pulmonary shunt
of 45%). A cardiac catheterization excluded pulmonary hyperten-
sion, and the diagnosis of HPS and indication for OLT were
conﬁrmed.
Since he was to shortly undergo major surgery, it was decided
to switch from sirolimus (which has been associated with greater
wound-healing problems) [7] to MMF 500 mg twice daily.
The patient returned to Portugal, and for the next 5 months
we saw an improvement in pulmonary symptoms, and complete
normalization of liver enzymes (not previously achieved).
The indication for OLT was suspended. Nine months after ini-
tiating MMF, he was independent of oxygen supply and had no
restrictions to physical activity. The physical signs of HPS (cyano-
sis, digital clubbing and spider nevi) had completely disappeared
(Fig. 1D and E). Laboratory investigations were as follows: tBil:
0.59 mg/dl, AST 28 UI/L, ALT 28 UI/L, GGT 48 UI/L, IgG 918 mg/
dl, peripheral blood double-negative (CD4/CD8) T cell 14,3%.
The PaO2 was normal (pH 7.398, PaO2 98.7 mmHg, PaCO2
42.5 mmHg, Hgb 14.3 g/dl, Sat O2 97.6%, oxi Hgb 97.3%, carboxi
Hgb 0,3%, met Hgb 0.0%, deoxi Hgb 2.4%) and intrapulmonary
vascular shunt was null. However, liver histology and upper
endoscopy showed that liver disease remained with signs of por-
tal hypertension (liver histology showed ﬁbrous expansion of
portal areas with ﬁbrous septa and bridging ﬁbrosis that incom-
pletely drafted nodules and features that suggested alterations in
the vascular ﬂow; upper endoscopy showed grade II varix in the
lower esophagus and mild hypertensive gastropathy).
In the following 12 months, prednisolone was reduced from
10 mg/day to 5 mg/day (while keeping MMF 500 mg twice/day).
Progressively, lymphadenopathy returned and spleen size raised
(reached 22 cm). Laboratory investigations conﬁrmed the pres-
ence of lymphocytosis, and elevated liver enzymes (2 times/nor-
mal values). Despite recurrence of lymphoproliferation, signs or
symptoms of HPS did not recur. Lymphoproliferation and liver
enzymes abnormalities had a satisfactory response to an
increased dose of prednisolone (40 mg/day), but response was
never complete and was steroid-dependent. About 24 months632 Journal of Hepatology 201after initiating MMF, sirolimus (1 mg/day) was added, and
2 weeks later there was already a massive reduction of lymph
nodes and spleen size (now 11.8 cm), as well as a complete nor-
malization of liver enzymes, and ﬁnally, we could rapidly reduce
steroids doses.
Discussion
The pathogenesis of HPS is complicated and remains incom-
pletely understood. Our current knowledge is mainly drawn from
experimental studies using animal models, and less is known
about human HPS and how the mechanisms identiﬁed in the
development of experimental HPS contribute to human disease.
The pathogenic hallmark of HPS (in both experimental models
and humans) is microvascular alterations within the pulmonary
arterial circulation. Excess pulmonary production of gaseous
vasodilators, including nitric oxide (NO) [8] and carbon monoxide
(CO), contributes to vasodilatation in the lung [9]. The increased
pulmonary vascular endothelial nitric oxide synthase (eNOS) is
the major source of pulmonary NO production in the animal
model, and the increased hepatic production and release of endo-
thelin-1 (ET-1) are important triggers of eNOS activation. Pul-
monary production of CO by intravascular macrophages is also
increased. These cells transiently produce inducible nitric oxide
synthase (iNOS) and progressively produce heme oxygenase 1
(HMOX1), and contribute to vasodilatation through production
of iNOS-derived NO and HMOX1-derived CO. iNOS is activated
by interferon-gamma (IFN-c) as a single signal, or by tumor
necrosis factor-a (TNF-a) along with a second signal [9]. Angio-
genesis, the process of growth of new vessels and capillary net-
works, is tightly regulated by angiogenic factors, in part
through vascular endothelial growth factor (VEGF)-dependent
pathways, leading to pulmonary capillary proliferation and arte-
riovenous malformations [9]. Recently, it has been demonstrated
that intravascular accumulation of activated macrophages in
small pulmonary arteries plays a central role in the pathogenesis
of HPS, since macrophages secrete vasodilating (iNOS), angio-
genic (VEGF), and proliferating growth factors [10].
Currently, OLT is the only established effective therapy for
HPS based upon the total resolution or signiﬁcant improvement
in gas exchange postoperatively in more than 85% of reported
patients, including children [5,6]. There are no known effective
medical therapies, although NO-synthase inhibitors have been
tried [11], and there are some anecdotal reports of patients with
spontaneous resolution of HPS [12].
Our patient started to improve from HPS after sirolimus was
switched to MMF and evolved to complete resolution in approx-
imately 9 months, following a similar path as patients submitted
to OLT. Some known mechanisms of action of MMF might explain
this outcome. MMF blocks cytokine (INF-c, TNF-a)-induced NO
production in endothelial rodent cells [13]. Although the regula-
tion of iNOS is mainly transcriptional, MMF exerts is effect on
endothelial cells through suppression of inosine monophosphate
dehydrogenase (IMPDH)-dependent synthesis of the essential
iNOS co-factor tetrahydrobiopterin (BH4), and subsequently,
iNOS enzymatic activity. In ﬁbroblasts, MMF inhibits NO produc-
tion by blocking guanosine nucleotide-dependent expression of
iNOS gene, through mechanisms that might involve the inhibi-
tion of the expression of the iNOS transcription factor IRF-1.
MMF might exert its inhibitory action on iNOS expression mainly
by interfering with IFN-c-derived signals. These MMF effects are3 vol. 58 j 630–633
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clearly demonstrated, at concentrations well below non-toxic
levels achievable in vivo, in rodent ﬁbroblasts, but not in macro-
phages [13]. MMF also reduces ET-1 synthesis in endothelial cells
and by this way can also inhibit NO production [14]. Moreover,
MMF is a potent inhibitor of endothelial cell and ﬁbroblast prolif-
eration and invasion/migration, and exerts its antiangiogenic
activity, in a dose-dependent way, by downregulating a regula-
tory network that consists of high- and low-degree nodes remi-
niscent of a scale-free network [15].
The mechanism by which MMF resolved HPS in our patient is
unclear. The time of resolution suggests an effect on angiogene-
sis, similar to what we observe after OLT. Yet, this successful out-
come might have been due to a combination of effects, including
the inhibition of both angiogenesis and NO synthesis. In fact, in
the animal model, depletion of intravascular pulmonary macro-
phages, implicated in HPS pathogenesis in several pathways,
reversed HPS, while inhibition of iNOS alone did not [10]. It
was previously reported that NO-synthase inhibitors alone in
HPS did not work, although they were never tried in a long-term
therapy, as happened with our patient [11].
There are anecdotal reports of cases in which HPS resolved
after portal hypertension was managed by transjugular intrahe-
patic portosystemic shunt [12]. In our patient, portal hyperten-
sion signs are still present while HPS resolved completely.
In conclusion, the development of medical treatment for HPS
is of major importance, since it will allow the elimination of ‘‘pri-
ority criteria’’ when patients are enrolled in the OLT list, and in
many patients will allow OLT to be postponed to a future date
to be deﬁned.
The report of this case study sheds some light on new medical
treatments for HPS, and opens the way for research and clinical
trials with angiogenesis and NO-inhibitors (MMF or others) on
a long-term treatment basis.Conﬂict of interest
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